Floatz logo

Rotigotine

Nervous System Diseases

I.R.C.C.S. Fondazione Santa LuciaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Nervous System Diseases cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Ginkgolide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Rotigotine is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
Nocturnal HypokinesiaDormant
BB
Indicative ·
65 / 100
View asset →
anxiety disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →